Evidence map›Paper›PMID 25942459›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Bret J Rudy, Bill G Kapogiannis, Carol Worrell, Kathleen Squires, James Bethel, Su Li, Craig M Wilson, Allison Agwu, Patricia Emmanuel, Georgine Price and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2018
    Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Bret J Rudy*New York University School of Medicine, New York, NY; †The Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health, Bethesda, MD; ‡Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA; §Westat, Rockville, MD; ‖University of Alabama at Birmingham; ¶Johns Hopkins School of Medicine; #University of South Florida School of Medicine, Tampa, FL; **University of Florida Health Science Center, Gainsville, FL; and ††Duke University School of Medicine, Durham, NC.
Bill G Kapogiannis
Carol Worrell
Kathleen Squires
James Bethel
Su Li
Craig M Wilson
Allison Agwu
Patricia Emmanuel
Georgine Price
Stephanie Hudey
Maureen M Goodenow
John W Sleasman
Adolescent Trials Network for HIVAIDS Interventions
Westat (United States) · USNational Institutes of Health · USUniversity of South Florida · USDuke University · USNew York University · USThomas Jefferson University · USUniversity of Alabama at Birmingham · USUniversity of Florida Health Science Center · US

Funding

Adol. Medicine Trials Network for HIV/AIDS InterventionsU01HD040474 · NICHD · WESTAT, INC. · PI HARRIS, DONALD ROBERT · 2001 to 2016
$114.4M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
LEADERSHIP GROUP FOR ADOLESCENT MEDICINE TRIALS NETWORKU01HD040533 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, CRAIG M · 2001 to 2016
$76.4M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
UVDM01RR010284 · NCRR · HOWARD UNIVERSITY · PI TAYLOR, ROBERT E. · 1996 to 2010
$17.4M
ZAP-70 EXPRESSION, CD38 EXPRESSION AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIAM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI MIRZA, NAZRAT · 2005 to 2010
$13.8M
Adolescent Trials Unit at The Children's Hospital of PhiladelphiaU01HD040481 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI DOUGLAS, STEVEN DANIEL · 2001 to 2015
$11.4M
Tampa Bay Adolescent Medicine Trial UnitU01HD040497 · NICHD · UNIVERSITY OF SOUTH FLORIDA · PI EMMANUEL, PATRICIA J · 2001 to 2015
$7.3M
Substance Use and Immunity in HIV+ Adolescents by Systems BiologyR01DA031017 · NIDA · UNIVERSITY OF FLORIDA · PI YIN, LI · 2010 to 2014
$4.4M
Johns Hopkins Adolescent Medicine Trials UnitU01HD068070 · NICHD · JOHNS HOPKINS UNIVERSITY · PI AGWU, ALLISON L · 2011 to 2015
$1.7M
NCATS NIH HHS UL1 TR001082NCRR NIH HHS M01 RR010284NCRR NIH HHS M01 RR020359NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025780NICHD NIH HHS U01 HD 040474NICHD NIH HHS U01 HD040474NICHD NIH HHS U01 HD040481NICHD NIH HHS U01 HD040497NICHD NIH HHS U01 HD 040533NICHD NIH HHS U01 HD040533NICHD NIH HHS U01 HD068070NIDA NIH HHS DA031017NIDA NIH HHS R01 DA031017NIDA NIH HHS R01 DA DA031017PHS HHS U01 A1068632
6 · The paper itself

Abstract

backgroundMeasures of immune outcomes in youth who initiate combination antiretroviral therapy (cART) early in HIV infection are limited.

designAdolescent Trials Network 061 examined changes over 48 weeks of cART in T-cell subsets and markers of T-cell and macrophage activation in subjects with pre-therapy CD4 > 350 cells/mm. All subjects had optimal viral suppression from weeks 24 through 48.

methodsSubjects (n = 48) initiated cART with tenofovir/emtricitabine plus ritonavir-boosted atazanavir. Data were collected at baseline and weeks 12, 24, and 48. Trends were compared to uninfected controls.

resultsSignificant increases over 48 weeks were noted in all CD4 populations, including total, naive, central memory (CM), and effector memory RO (EM RO) and effector memory RA (EM RA), whereas numbers of CM and EM RO CD8 cells declined significantly. By week 48, CD4 naive cells were similar to controls, whereas CM CD4 cells remained significantly lower and EM RO and EM RA subsets were significantly higher. CD38 and HLA DR expression, both individually and when co-expressed, decreased over 48 weeks of cART on CD8 cells but remained significantly higher than controls at week 48. In contrast, markers of macrophage activation measured by sCD14 and sCD163 in plasma did not change with cART and were significantly higher than controls.

conclusionsIn youth initiating early cART, CD4 cell reconstitution is robust with decreases in CD8 cells. However, CD8 T-cell and macrophage activation persists at higher levels than uninfected controls.

Indexed as

Antiretroviral Therapy, Highly ActiveLymphocyte ActivationMacrophage ActivationAdolescentAnti-HIV AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCohort StudiesFemaleHIV InfectionsHumansMaleTime FactorsYoung AdultAnti-HIV Agents

Identifiers

PMID25942459
PMCPMC4452031
OpenAlexW2331163517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.